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Abstract Some synthetic agonists of the VR1 vanilloid
(capsaicin) receptor also inhibit the facilitated transport into
cells of the endogenous cannabinoid anandamide (arachidonoyl-
ethanolamide, AEA). Here we tested several AEA derivatives
containing various derivatized phenyl groups or different alkyl
chains as either inhibitors of the AEA membrane transporter
(AMT) in intact cells or functional agonists of the VR1 vanilloid
receptor in HEK cells transfected with the human VR1. We
found that four known AMT inhibitors, AM404, arvanil, olvanil
and linvanil, activate VR1 receptors at concentrations 400^
10 000-fold lower than those necessary to inhibit the AMT.
However, we also found three novel AEA derivatives, named
VDM11, VDM12 and VDM13, which inhibit the AMT as
potently as AM404 but exhibit little or no agonist activity at
hVR1. These compounds are weak inhibitors of AEA enzymatic
hydrolysis and poor CB1/CB2 receptor ligands. We show for the
first time that, despite the overlap between the chemical moieties
of AMT inhibitors and VR1 agonists, selective inhibitors of AEA
uptake that do not activate VR1 (e.g. VDM11) can be
developed. ß 2000 Federation of European Biochemical Soci-
eties. Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
Two receptors for the psychoactive ingredient of marijuana,
v9-tetrahydrocannabinol (THC), the CB1 and CB2 cannabi-
noid receptors, have been found (see [1] for review). Arach-
idonoylethanolamide (AEA), better known as anandamide,
acts as an endogenous CB1 receptor agonist [2]. Termination
of the activity of AEA by cells is achieved through a two-step
process including: (i) re-uptake by intact cells via the ‘anand-
amide membrane transporter’ (AMT) and (ii) hydrolysis of
the amide bond, catalyzed by the enzyme ‘fatty acid amide
hydrolase’ (FAAH) ([3^6], and [7] for a recent review). An-
other receptor for a bioactive plant lipid component, capsaicin
(Table 1), which is responsible for the pungent taste of ‘hot’
chili peppers [8], was recently characterized. This receptor,
also known as the ‘vanilloid’ receptor, is a ligand-gated un-
selective cation channel, and was named VR1 [9].
The chemical similarity between AEA and the potent ligand
of vanilloid receptors, olvanil [10] (Table 1), suggested that
certain vanilloids might interact with cannabinoid receptors,
the AMT, or FAAH, and that, conversely, AEA might acti-
vate VR1 receptors. Both these hypotheses found strong sup-
port in recent experimental reports. It was found that olvanil
has an a⁄nity for CB1 (Ki = 1.6 WM) only slightly lower than
that observed for VR1 receptors (Ki = 0.4 WM) [11,12]. Olvanil
also inhibits the AMT in rat basophilic leukemia (RBL-2H3)
cells (IC50 = 9 WM) without in£uencing FAAH activity [12].
Capsaicin was inactive or very weakly active in these assays.
A chemical ‘hybrid’ between AEA and capsaicin, named ar-
vanil (Table 1), was found to be a more potent ligand of CB1
receptors (Ki = 0.25^2.6 WM) and inhibitor of the AMT
(IC50 = 3.6 WM) than olvanil [13]. This compound and olvanil
are partial agonists at CB1 receptors [12,14]. Another capsai-
cin homologue and AMT inhibitor (IC50 = 8 WM), linvanil
(Table 1), enhances AEA actions in vitro [15] and exhibits
low a⁄nity for CB1 receptors (Ki = 3.4 WM) [13]. Arvanil
and linvanil appear to be agonists at VR1 receptors, but no
full assessment of their functional activity has been performed
to date. Interestingly, not only do some VR1 ligands inhibit
the AMT but also the AMT inhibitor N-(4-hydroxyphenyl)-
arachidonylamide (better known as AM404 [16], (Table 1)) is
a full agonist at VR1 with a⁄nity and e⁄cacy at least 10-fold
higher than those for the AMT [17^19]. Parallel to these ¢nd-
ings, AEA was shown to act as a full agonist at both rat and
human VR1 receptors, either native, in perivascular and dor-
sal root sensory neurons, or over-expressed in human embry-
onic kidney (HEK) cells and Xenopus oocytes [20,21]. The
possibility that AEA represents the physiological endogenous
ligand of VR1 receptors is being currently debated [19,23^25].
These observations (a) impose that great caution be taken in
the interpretation of data obtained by using AEA or inhib-
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itors of the AMT in pharmacological studies in vivo, partic-
ularly as VR1 receptors have been recently found in brain
regions, such as the basal ganglia, hippocampus and hypo-
thalamus, that also contain CB1 receptors and AEA [25^
28]; and (b) prompt the development of more selective
AMT inhibitors, a task that we have undertaken in this study.
Furthermore, these data indicate a partial overlap between the
structural requirements of VR1 and AMT binding sites [25],
which here we have investigated further.
2. Materials and methods
2.1. Transfected cells
Over-expression of hVR1 cDNA into human embryonic kidney
(HEK) 293 cells was carried out as described previously [22]. Cells
were grown as monolayers in minimum essential medium supple-
mented with non-essential amino acids, 10% fetal calf serum and
0.2 mM glutamine, and maintained under 95%/5% O2/CO2 at 37‡C.
2.2. Compounds
Capsaicin, AM404, AEA, palmitoylethanolamide and 2-arachido-
noyl-glycerol were purchased from Cayman Chemicals (Ann Arbor,
Table 1
Chemical structures of the fatty acid derivatives tested in this study and their e¡ect on hVR1-mediated Ca2 in£ux into hVR1-HEK293 cells
and on the anandamide membrane transporter (AMT) in RBL-2H3 and C6 glioma cells
In the former case, both potency (EC50) and e⁄cacy (as % of the response obtained with 4 WM ionomycin) are reported. For the AMT, data
for potency of inhibition (IC50) of [14C]anandamide uptake are shown. Data are means þ S.D. of n = 3 separate experiments. NM, e⁄cacy was
too little to measure EC50 ; ND, not determined. N-AVAM, N-acyl-vanillyl-amine.
aData are from [13].
bData are from [33].
FEBS 24190 6-10-00
L. De Petrocellis et al./FEBS Letters 483 (2000) 52^56 53
MI, USA). HU-210 was a gift from Dr. R. Mechoulam, Hebrew
University of Jerusalem, Israel. N-acyl-vanillyl-amines (N-AVAMs)
were synthesized as described in [12,13]. Arachidonoyl-glycine was a
gift from Dr. S. Burnstein, University of Massachussetts, USA.
Arachidonoyl-dopamine, VDM11, VDM12 and VDM13 (Table 1)
were synthesized from the corresponding amines and arachidonoyl-
chloride (all from Sigma) in di-methyl-formamide, in the presence of
1.1 equivalents of triethylamine for 18 h at 4‡C. The reaction was
stopped by adding water and by extracting the products with diethyl
ether. The compounds were puri¢ed by direct phase high pressure
liquid chromatography, and chemical structures con¢rmed by means
of proton nuclear magnetic resonance and infrared spectroscopy.
2.3. Ca2+ in£ux assays
The e¡ect of the substances on the in£ux of Ca2 into cells was
determined by using Fluo-3, a selective intracellular £uorescent probe
for Ca2. Four days prior to experiments cells were transferred into
six-well dishes coated with poly-L-lysine (Sigma) and grown in the
culture medium mentioned above. The day of the experiment the cells
(50^60 000 per well) were loaded for 2 h at 25‡C with 4 WM Fluo-3
methylester (Molecular Probes) in DMSO containing 0.04% Pluor-
onic. After the loading, cells were washed with Tyrode pH = 7.4,
and trypsinized to be suspended in the cuvette of the £uorescence
detector (Perkin-Elmer LS50B) under continuous mixing. Experiments
were carried out by measuring cell £uorescence at 25‡C (VEX = 488
nm, VEM = 540 nm) before and after the addition of the test com-
pounds at various concentrations. Capsazepine (1^5 WM) or EGTA
(4 mM) were added 30 or 10 min, respectively, before the test com-
pounds. Data are expressed as the concentration exerting a half-max-
imal e¡ect (EC50) calculated by using GraphPad software. The e⁄-
cacy of the e¡ect was determined by comparing it to the analogous
e¡ect observed with 4 WM ionomycin.
2.4. FAAH activity assays
N18TG2 cells were cultured as described previously ([12,13] and
references cited therein). The e¡ect of compounds on the enzymatic
hydrolysis of [14C]AEA (6 WM) was studied by using membranes
prepared from N18TG2 cells incubated with increasing concentrations
of compounds in 50 mM Tris^HCl, pH 9, for 30 min at 37‡C [12,13].
[14C]Ethanolamine produced from [14C]AEA hydrolysis was measured
by scintillation counting of the aqueous phase after extraction of the
incubation mixture with 2 volumes of CHCl3/CH3OH 2:1 (by vol).
2.5. AEA transporter assays
The e¡ect of compounds on the uptake of AEA by RBL-2H3 cells
was studied by a modi¢cation of the method described previously
[6,12,13], and analogous to the protocol described in [5,16] except
for the use of a higher concentration (4 WM) of [14C]AEA. Cells
were incubated with [14C]AEA for 5 min at 37‡C, in the presence or
absence of varying concentrations of the inhibitors. Residual
[14C]AEA in the incubation media after extraction with CHCl3/
CH3OH 2:1 (by vol), determined by scintillation counting, was used
as a measure of the AEA that was taken up by cells. We applied the
same protocol also to C6 rat glioma cells, which also contain a mem-
brane transporter for AEA [3]. Data are expressed as the concentra-
tion exerting 50% inhibition of AEA uptake (IC50) calculated with
GraphPad.
2.6. CB1 and CB2 receptor binding assays
Displacement assays for CB1 receptors were carried out by using
[3H]SR141716A (0.4 nM, 55 Ci/mmol, Amersham) as the high a⁄nity
ligand, and the ¢ltration technique previously described [12^14], on
membrane preparations (0.4 mg/tube) from frozen male CD rat brains
(Charles River, Italia), and in the presence of 100 WM PMSF. Speci¢c
binding was calculated with 1 WM SR141716A (a gift from Sano¢
Recherche, France) and was 84.0%. The spleen from CD rats were
used to prepare membranes (0.4 mg/tube) to carry out CB2 binding
assays by using [3H]WIN55,212-2 (0.8 nM, 50.8 Ci/mmol, NEN-Du-
pont) as described previously [14], and again in the presence of 100
WM PMSF. Speci¢c binding was calculated with 1 WM HU-348 (a gift
from Prof. R. Mechoulam and Pharmos) and was 75.0%. In all cases,
Ki values were calculated by applying the Cheng^Pruso¡ equation to
the IC50 values (obtained by GraphPad) for the displacement of the
bound radioligand by increasing concentrations of the test com-
pounds.
3. Results and discussion
In the present study we have carried out the full character-
ization of the functional activity at the human VR1 (hVR1)
receptor of several AEA derivatives, including the previously
reported N-AVAMs [13] and AM404 [16], as well as the ¢ve
new synthetic compounds: arachidonoyl-dopamine, arachido-
noyl-glycine, VDM11, VDM12 and VDM13 (Table 1). AEA,
N-AVAMs, AM404 and arachidonoyl-dopamine behaved as
both potent and full agonists at the hVR1, as assessed by
measuring their stimulation of Ca2 in£ux into hVR1-HEK
cells (Table 1, Fig. 1). VDM12 was also a full agonist in
this assay, although it was almost two orders of magnitude
less potent than AEA. Arachidonoyl-glycine, VDM11 and
VDM13 were almost totally devoid of VR1 agonist activity.
Fig. 1. (A) Dose^response curves for the e¡ects of capsaicin, anand-
amide, arvanil and arachidonoyl-dopamine (AA-DA) on hVR1-
mediated Ca2 in£ux into hVR1-HEK293 cells. In order to show
the di¡erence in potency among various agonists the e¡ect is ex-
pressed as % of maximal response obtained for each agonist. The
maximal responses for each agonist (as % of the e¡ects observed
with 4 WM ionomycin) are reported in Table 1. Data are means of
n = 3 di¡erent experiments. Error bars are not shown for the sake
of clarity and were never higher than 10% of the means. The e¡ect
of EGTA (4 mM) on the response obtained with anandamide and
arvanil is shown. Capsazepine (5 WM) reduced the e¡ect of all ago-
nists (including those shown in panel B) to 0%. (B) Dose^response
curves for the e¡ects of linvanil, AM404, VDM11, VDM12 and
VDM13 on hVR1-mediated Ca2 in£ux into hVR1-HEK293 cells.
In order to show the di¡erence in both potency and e⁄cacy among
various agonists, the e¡ect is expressed as % of the response ob-
tained with 4 WM ionomycin. Data are means of n = 3 di¡erent ex-
periments. S.D. bars are not shown for the sake of clarity and were
never higher than 10% of the means.
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2-Arachidonoyl-glycerol, palmitoylethanolamide or the syn-
thetic cannabinoid HU-210 only induced a small stimulation
of Ca2 in£ux into hVR1-HEK cells, in agreement with pre-
vious studies [20,21]. The e¡ects of all the most potent com-
pounds were abolished by 1^5 WM capsazepine, an antagonist
of vanilloid receptors [29], or by 4 mM EGTA (Fig. 1 and
data not shown), which chelates extracellular Ca2 thus pre-
venting VR1-mediated Ca2 in£ux into the cells [30]. Only a
small e¡ect on Ca2 in£ux could be observed with the most
potent compounds in non-transfected HEK cells at the highest
concentrations used (1034^1035 M, data not shown). In this
case the e¡ect was not a¡ected by EGTA. These data indicate
that all the compounds found here to activate Ca2 in£ux do
so by acting through the hVR1 receptor.
Arvanil and its 18:3g6 homologue are among the most
potent activators of hVR1 reported so far, with EC50 values
of 0.5^0.7 nM, comparable to and lower than those of olvanil
and capsaicin, respectively (Table 1). In the N-AVAM series,
the rank of potency was as follows: arvanil = olvanilv
18:3g6s linvanilv palvanils capsaicin. Therefore, unlike na-
tive rodent vanilloid receptors [31,32], the hVR1 seems to
prefer as agonists long chain, unsaturated N-AVAMs to cap-
saicin. Furthermore, olvanil is respectively as potent as or
more potent than capsaicin at activating rat or human VR1
over-expressed in HEK cells, respectively [18]. These data, if
supported by further experiments, may suggest di¡erent sub-
strate speci¢cities for hVR1, rat VR1 and the possibly hetero-
geneous population of rat native vanilloid receptors [8,10].
The rank of potency observed here for N-AVAMs on hVR1
is similar to that previously reported for the inhibition of the
AMT by the same compounds: arvanilv 18:3g6v olvanilv
linvanilEpalvanil = capsaicin [13]. Although in the case of
the AMT palvanil and capsaicin were almost inactive, these
data support the concept of a partial overlap between the
ligand recognition properties of the AMT and hVR1 [25]. In
support of the importance of the arachidonate moiety for
recognition by both hVR1 and the AMT, we found that
two AEA derivatives (and AMT inhibitors), arachidonoyl-
dopamine [33] and AM404 [16], also potently activate hVR1
(Fig. 1, Table 1). Both compounds were at least 10-fold less
potent than arvanil, on Ca2 in£ux, in agreement with pre-
vious reports [34] that the addition or deletion of one meth-
ylene group between the amide and the phenol groups in
capsaicin causes a 10-fold loss of potency at rat native vanil-
loid receptors [34]. More importantly, these data con¢rm that
AM404 is much more potent as a VR1 agonist [17^19] than as
an inhibitor of the AMT, and emphasize the necessity of more
selective AMT inhibitors, particularly for in vivo studies on
the mechanisms controlling the duration of AEA action. In-
terestingly, the dose^response curve for AM404, unlike that of
capsaicin or AEA, was not a sigmoid (Fig. 1). This may sug-
gest that this compound does not interact with hVR1 in the
same way as the other vanilloid agonists.
Although a necessary prerequisite, a polyunsaturated fatty
acid chain is not su⁄cient alone for potent activation of
hVR1. In fact, we found that the other endogenous ligand
of cannabinoid receptor, 2-arachidonoyl-glycerol, and another
AEA analogue, arachidonoyl-glycine, are almost inactive on
hVR1 receptors (Table 1). Interestingly, both compounds
were also very weak or inactive as inhibitors of [14C]AEA
uptake, thus underlying the similarity between the AMT
and hVR1 ligand recognition properties. However, by intro-
ducing either a methyl or a hydroxyl group in the ortho posi-
tion of AM404 we synthesized two compounds, VDM11 and
VDM12, that although still very active as inhibitors of the
AMT (Table 1), were either entirely devoid of agonist activity
at hVR1 or much less potent (Fig. 1b). VDM11, the o-methyl
derivative of AM404, up to 40 WM, only produced a hardly
noticeable e¡ect on Ca2 in£ux into hVR1-transfected cells
and yet it exhibited an IC50 for AMT inhibition of about
10^11 WM. VDM12, the o-hydroxyl derivative of AM404,
induced an e⁄cacious agonist response in hVR1-transfected
cells only at 40 WM, whereas at the concentrations exerting a
half-maximal inhibition of [14C]AEA transport into cells (Ta-
ble 1), produced a very weak agonist e¡ect on hVR1. VDM13
(arachidonoyl-5-methoxytryptamine) was completely inactive
at VR1 even at very high doses, while it was equipotent to
VDM11 and VDM12 on the AMT. Under the same experi-
mental conditions AM404 was equipotent to VDM11,
VDM12 and VDM13 as an AMT inhibitor (Table 1). Finally,
none of the three new compounds antagonized capsaicin ac-
tion at hVR1 receptors (at 1 WM and with a 30 min pre-
incubation, data not shown). Therefore, VDM11, VDM12
and VDM13 are much more selective on AEA facilitated
transport vs. vanilloid receptors than the most widely used
AMT inhibitor, AM404. We also wanted to assess the a⁄nity
of these new compounds for FAAH and the CB1/CB2 canna-
binoid receptors. VDM11, VDM12 and VDM13 weakly in-
hibited [14C]AEA hydrolysis by N18TG2 cell membranes
(IC50s 50 or = 25 þ 1.6 and 27 þ 0.9 WM, respectively). Under
the same conditions AM404 was slightly more potent, with an
IC50 of 22 þ 0.7 WM. Finally, when tested in cannabinoid re-
ceptor binding assays carried out with rat brain or spleen
membranes, VDM11, VDM12 and VDM13 produced a ligand
displacement lower than 50% up to 5^10 WM concentrations
(Kis 5^10 WM in all cases). Therefore, these compounds,
apart from being inactive on CB2 receptors, are weaker CB1
ligands than AM404, arvanil or linvanil, whose Ki values for
CB1 receptors are 1.76, 0.5^2.6 and 3.4 WM, respectively
[13,14,35]. In summary, by being more selective than previ-
ously described AMT inhibitors in all the assays performed
here, these novel compounds, and VDM11 in particular, can
be proposed as useful pharmacological tools for the study of
the role of the AMT in the physiological termination of AEA
action. In agreement with the high selectivity of these com-
pounds, we found that, unlike AM404 [17], VDM11 and
VDM12 do not relax the rat mesenteric artery (a process
mediated by VR1 and cannabinoid receptors [17,36]), nor
do they inhibit human breast cancer cell proliferation (a
CB1-mediated e¡ect [37]) if not at very high doses (V. Di
Marzo, D. Melck, Z. Ja¤rai, T. Bisogno and G. Kunos, un-
published observations).
In conclusion, we provided evidence for partially overlap-
ping ligand recognition properties of hVR1 and the AMT.
Based on these studies, we have identi¢ed possible chemical
modi¢cations that may allow AEA analogues to distinguish
between hVR1 and the AMT, and have developed novel and
selective inhibitors of the latter protein that promise to be
fundamental tools for the study of AEA inactivation in vivo.
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